Is NCT05256641 recruiting in Sacramento, CA?

Yes, NCT05256641 is currently recruiting participants at its Sacramento, CA location. This large b-cell lymphoma clinical trial is actively enrolling qualified participants.

How do I join the large b-cell lymphoma clinical trial in Sacramento?

To join this clinical trial in Sacramento, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Sacramento clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Large B-cell Lymphoma Clinical Trial in Sacramento, CA

About This Large B-cell Lymphoma Study in Sacramento

This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.

Sponsor: Jonsson Comprehensive Cancer Center

Who Can Participate

Inclusion Criteria

Ages 18-70 years

One of the following:

Patients undergoing autologous stem cell transplantation (ASCT) or any Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T-cell therapy product for:

High grade B-cell lymphoma (double or triple hit) with rearrangements in bcl-2 and/or bcl-6, and rearrangement in myc

Large B-cell lymphoma with a history of secondary CNS involvement

Histologic transformation of indolent lymphoma to large B-cell lymphoma, including marginal zone lymphoma, follicular lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphoplasmacytic leukemia, or Waldenstrom macroglobulinemia

High risk international prognostic index (IPI) score 4 or 5, at diagnosis or prior to CAR T-cell leukapheresis

Patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for large B-cell lymphoma

Eastern Cooperative Oncology Group (ECOG) 0-2

Requirements for post-ASCT and post-alloHCT participants:

Disease status of partial response (PR) or complete response (CR) prior to transplantation

Receive reduced-intensity conditioning regimen

Enrollment no later than day +90

Requirements for post-CAR T-cell therapy participants:

Disease status of PR or CR after post-CAR T-cell therapy positron emission tomography (PET)-computed tomography (CT) at 1-3 months

Enrollment no later than day +104

Ability to give full informed consent

Female subjects who are sexually active and can bear children must agree to use highly effective forms of contraception while on the study and for 2 days after the last dose of acalabrutinib

Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing capsules and tablets without difficulty

Absolute neutrophil count (ANC) \> 500/uL (microliters)

Platelets \> 50,000/uL independent of transfusions

Hemoglobin \> 8 g/dL independent of transfusions

Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x upper limit of normal (ULN)

Total bilirubin =\< 1.5 x ULN, unless directly attributable to Gilbert's syndrome

Creatinine clearance \>= 60 mL/min based on Cockcroft-Gault glomerular filtration rate (GFR) and serum creatinine (Cr) =\< 1.8 mg/dL

Exclusion Criteria

Cord blood as donor source in alloHCT

New York Heart Association Class III or IV

Left ventricular ejection fraction \< 50%

Estimated glomerular filtration rate \< 30 mL/min

Concurrent long-term use of posaconazole or other strong CYP3A4 inhibitors and unable to replace with equivalent medication

Acute or chronic graft-versus-host disease (GvHD) \>= stage 3 at time of enrollment

Received packed red blood cells (pRBC) transfusion within the past 2 weeks

Received platelet transfusion within the past 1 week

Active invasive fungal infection

Active bacterial or viral infection until resolution of the infection

History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML)

Received any investigational drug within 30 days or 5 half-lives (whichever is shorter) before first dose of study drug

Major surgical procedure within 30 days before the first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug

Refractory nausea and vomiting, inability to swallow the formulated product, or malabsorption syndrome; chronic gastrointestinal disease, gastric restrictions, or bariatric surgery such as gastric bypass; partial or complete bowel obstruction, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of study treatment

Received a live virus vaccination within 28 days of first dose of study drug

Known history of infection with human immunodeficiency virus (HIV)

History of bleeding diathesis (e.g., hemophilia, von Willebrand disease)

Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists

Requires treatment with a strong cytochrome P450 3A (CYP3A) inhibitor or inducer. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks of the first dose of study drug is prohibited

Breastfeeding or pregnant

Concurrent participation in another therapeutic clinical trial

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Sacramento?

Yes, this clinical trial (NCT05256641) has an active research site in Sacramento, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Large B-cell Lymphoma Treatment Options in Sacramento, CA

If you're searching for large b-cell lymphoma treatment options in Sacramento, CA, this clinical trial (NCT05256641) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Sacramento research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced large b-cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all large b-cell lymphoma clinical trials near you to find additional studies recruiting in your area.

Large B-cell Lymphoma Clinical Trial in Sacramento, CA

Expert Care in Sacramento

IRB Approved

No-Cost Care

Apply for This Sacramento Location

Why Participate?

Simple Process